Chemolipiodolization and prostaglandin E1 administration with use of hepatic arterial infusion port for the treatment of hepatocellular carcinoma and liver cirrhosis.
Frequent chemolipiodolization and prostaglandin E1 (PGE1) administered through a hepatic arterial infusion port were used for treatment in 2 cases of hepatocellular carcinoma (HCC) with liver cirrhosis. Chemolipiodolization was performed every 4 weeks with 6 ml lipiodol, 3 ml Optilay and 30 mg Epirubicin or 10 mg Mytomycin C. PGE1 (10 ug) was administrated to the hepatic artery once every week after the first 7 days administration. The treatment resulted in a decrease of the AFP level, an arrest of HCC growth and a reduction in ascites with an improvement of clinical and biochemical parameters in both cases. These encouraging preliminary results show that frequent lipiodolization is effective for unresectable HCC and frequent PGE1 administration via the hepatic artery is a safe and efficient treatment for liver cirrhosis.
Kakizoe
S
S
Department of Surgery, Kakizoe Hospital, Nagasaki, Japan.
Kakizoe
K
K
Kakizoe
Y
Y
Kakizoe
H
H
Kakizoe
T
T
Kakizoe
S
S
D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D003287:Contrast Media / Q000008:administration & dosage*; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007260:Infusion Pumps; D007459:Iodized Oil / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male
D003287:Contrast Media; D007459:Iodized Oil; D000527:Alprostadil